Skip to main content
. 2017 Oct 7;34(3):443–447. doi: 10.1007/s12288-017-0877-x

Table 2.

Outcomes of switching to nilotinib

Reason for switch to nilotinib Total N (%) Responded N (%) No response N (%) Stopped due to toxicity N (%)
Result of switching
Intolerance to imatinib 4 (10.8%) 4 (100%) 0 (0%) 0 (0%)
Loss of CHR 20 (54.1%) 14 (70%) 4 (20%) 2 (10%)
BC 3 (8%) 1 (33%) 2 (66%) –
Not achieved CHR 2 (5.4%) 0 (0%) 2 (100%) –
Loss of CCR/MMR 2 (5.4%) 0 (0%) 1 (50%) 1 (50%)
No achievement of CCR/MMR 6 (16%) 1 (17%) 3 (50%) 2 (33%)